MedDataX Logo

Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction

NCT ID: NCT00543036

Last Updated: 2007-10-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of efficacy and safety of H-coil deep transcranial magnetic stimulation 9 week treatment trial for cannabis addiction as assessed by measures of drug intake and craving.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Marijuana Abuse

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cannabis Addiction Craving TMS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

H-Coil deep TMS

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and Female, aged 21-70 years, who meet DSM-IV TR diagnostic criteria for cannabis abuse and are motivated to quit cannabis use as assessed in the screening visit and gave their written informed consent to participate in the study.

Exclusion Criteria

* History of a primary major psychiatric other then cannabis abuse, or cognitive disorder according to DSM-IV TR criteria.
* Hamilton depression scale rated 25 and above (moderate to severe depression)
* Current alcohol or other substance abuse or dependence
* Alcohol or other substance abuse or dependence during the last 12 months before recruitment.
* History of or evidence of significant brain malformation,neoplasm, head injury, cerebral vascular events,neurodegenerative disorder or brain surgery.
* Severe somatic co-morbidity
* History of seizures Cardiac pace maker or other electronic implants Pregnancy and lactation
Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shalvata Mental Health Center

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ziv Carmel, M.D

Role: PRINCIPAL_INVESTIGATOR

Shalvata MHC affiliated to Tel-Aviv universtiy, Sackler school of medicine

Abraham Zangen, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Weizmann Institute, Rehovot, Israel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shalvata Mental Health Center

Hod HaSharon, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ziv Carmel, M.D.

Role: CONTACT

Phone: +972-9-7478570

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ziv Carmel, M.D

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SH 30107

Identifier Type: -

Identifier Source: org_study_id